Trial Outcomes & Findings for Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies (NCT NCT00691210)

NCT ID: NCT00691210

Last Updated: 2020-11-20

Results Overview

• Recruitment status: COMPLETED
• Study phase: PHASE1
• Target enrollment: 40 participants
• Primary outcome timeframe: 3 years
• Results posted on: 2020-11-20

Participant Flow

Participant milestones

Measure	V/N: Level 2 Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 1 Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 3 Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 4 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 5 Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N/E: Level 1 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme	V/N/E: Level 2 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme	V/N/E: Level 3 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 100 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme
Overall Study STARTED	3	5	3	9	5	7	6	0
Overall Study COMPLETED	3	5	3	6	5	6	6	0
Overall Study NOT COMPLETED	0	0	0	3	0	1	0	0

Reasons for withdrawal

Measure	V/N: Level 2 Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 1 Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 3 Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 4 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 5 Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N/E: Level 1 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme	V/N/E: Level 2 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme	V/N/E: Level 3 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 100 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme
Overall Study Progression of Disease	0	0	0	2	0	0	0	0
Overall Study Lack of Efficacy	0	0	0	1	0	1	0	0

Baseline Characteristics

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

Baseline characteristics by cohort

Measure	V/N: Level 1 n=5 Participants Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 2 n=3 Participants Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 3 n=3 Participants Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 4 n=9 Participants Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N: Level 5 n=5 Participants Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	V/N/E: Level 1 n=7 Participants Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme	V/N/E: Level 2 n=6 Participants Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme	V/N/E: Level 3 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 100 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme	Total n=38 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	—	0 Participants n=42 Participants
Age, Categorical Between 18 and 65 years	5 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	7 Participants n=4 Participants	3 Participants n=21 Participants	6 Participants n=8 Participants	4 Participants n=8 Participants	—	30 Participants n=42 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	2 Participants n=4 Participants	2 Participants n=21 Participants	1 Participants n=8 Participants	2 Participants n=8 Participants	—	8 Participants n=42 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	4 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=8 Participants	2 Participants n=8 Participants	—	15 Participants n=42 Participants
Sex: Female, Male Male	3 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	5 Participants n=4 Participants	3 Participants n=21 Participants	5 Participants n=8 Participants	4 Participants n=8 Participants	—	23 Participants n=42 Participants

PRIMARY outcome

Timeframe: 3 years

Population: There were no evaluable patients at these levels.

Outcome measures

Measure	Vorinostat (SAHA) and Niacinamide: Level 1 n=22 Participants Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 2 Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 3 Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 4 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 5 Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat, Niacinamide and Etoposide: Level 1 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme	Vorinostat, Niacinamide and Etoposide: Level 2 Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme
The Maximum Tolerated Dose (MTD) of Niacinamide in the Combination of Vorinostat and Niacinamide	100 mg/kg	—	—	—	—	—	—

SECONDARY outcome

Timeframe: up to 45 weeks

The highest number of cycles received by an individual participant in the treatment groups. Each cycle was 21 days long.

Outcome measures

Measure	Vorinostat (SAHA) and Niacinamide: Level 1 n=5 Participants Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 2 n=3 Participants Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 3 n=3 Participants Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 4 n=6 Participants Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 5 n=5 Participants Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat, Niacinamide and Etoposide: Level 1 n=6 Participants Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme	Vorinostat, Niacinamide and Etoposide: Level 2 n=5 Participants Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme
The Greatest Number of Cycles Received in Each Treatment Group	9 cycles	12 cycles	15 cycles	10 cycles	14 cycles	3 cycles	4 cycles

SECONDARY outcome

Timeframe: continuous

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: continuous

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: continuous

Outcome measures

Outcome data not reported

Adverse Events

Vorinostat (SAHA) and Niacinamide: Level 1

Serious events: 2 serious events

Other events: 5 other events

Deaths: 0 deaths

Vorinostat (SAHA) and Niacinamide: Level 2

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

Vorinostat (SAHA) and Niacinamide: Level 3

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Vorinostat (SAHA) and Niacinamide: Level 4

Serious events: 5 serious events

Other events: 9 other events

Deaths: 0 deaths

Vorinostat (SAHA) and Niacinamide: Level 5

Serious events: 3 serious events

Other events: 5 other events

Deaths: 0 deaths

Vorinostat, Niacinamide and Etoposide: Level 1

Serious events: 2 serious events

Other events: 7 other events

Deaths: 0 deaths

Vorinostat, Niacinamide and Etoposide: Level 2

Serious events: 1 serious events

Other events: 6 other events

Deaths: 0 deaths

Serious adverse events

Measure	Vorinostat (SAHA) and Niacinamide: Level 1 n=5 participants at risk Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 2 n=3 participants at risk Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 3 n=3 participants at risk Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 4 n=9 participants at risk Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 5 n=5 participants at risk Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat, Niacinamide and Etoposide: Level 1 n=7 participants at risk Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme	Vorinostat, Niacinamide and Etoposide: Level 2 n=6 participants at risk Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme
Metabolism and nutrition disorders Acidosis	20.0% 1/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders ALT	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders AST	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Creatinine	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Hyperbilirubinemia	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Hyperkalemia	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Hypoalbuminemia	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Investigations Hypoglycemia	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Hyponatremia	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders INR	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Hepatobiliary disorders Liver Failure	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Pneumonia	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Pain	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	44.4% 4/9 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Thrombocytopenia	20.0% 1/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Uric Acid	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Vomiting	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders Hematuria	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
General disorders Fatigue	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
General disorders Fever	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
General disorders Nausea	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Anemia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Anorexia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Diarrhea	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
General disorders Death	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Vascular disorders DVT	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Hand-Foot Reaction	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Cardiac disorders Hypotension	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Leg Weakness & Numbness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Neutropenia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Sepsis	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Sensory Neuropathy	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Shortness of Breath	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Soreness in mouth	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations MSSA	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Syncope	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Chord Compression	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Cardiac disorders Tachycardia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Upper Respiratory Infection	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Weakness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
General disorders Cellulitis	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Rash	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Edema	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Hypokalemia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Hypomagnesemia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Hypophosphotemia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
General disorders Hypothermia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Infection	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Low CO2	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Urea Nitrogen	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Zoster	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Acute Dyspnea	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).

Other adverse events

Measure	Vorinostat (SAHA) and Niacinamide: Level 1 n=5 participants at risk Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 2 n=3 participants at risk Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 3 n=3 participants at risk Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 4 n=9 participants at risk Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat (SAHA) and Niacinamide: Level 5 n=5 participants at risk Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg Vorinostat (SAHA) and Niacinamide: dose escalation scheme	Vorinostat, Niacinamide and Etoposide: Level 1 n=7 participants at risk Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme	Vorinostat, Niacinamide and Etoposide: Level 2 n=6 participants at risk Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2 Vorinostat, Niacinamide and Etoposide: dose escalation scheme
Infections and infestations URI	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Acidosis	20.0% 1/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Cough	40.0% 2/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	44.4% 4/9 • Number of events 10 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	80.0% 4/5 • Number of events 9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	28.6% 2/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Diffuse PapilarRash ( hypersensitivity reaction)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Headache	40.0% 2/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	55.6% 5/9 • Number of events 11 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 8 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders 2 episodes of feeling weak & unbalanced	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders 3 Puncatate skin Leasions on Arm(mosquito bites)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Abdominal Bloating	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Abdominal Cramping	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Abdominal Discomfort	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Abdominal pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Ache	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Acid Reflux	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Acne (following RT)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Acute Dyspnea	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Agitated/Irritable Mood	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Alk Phos	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders ALT	40.0% 2/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Ammonia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders ANC	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Anemia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	28.6% 2/7 • Number of events 9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Anesthesia of Forehead	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Anorexia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	77.8% 7/9 • Number of events 14 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	42.9% 3/7 • Number of events 5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	50.0% 3/6 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Anxiety	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	28.6% 2/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Armpit Burning	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Aspergillus fumigatus	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders AST	40.0% 2/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Bacterial SuperInfections and infestations	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Bad Taste in Mouth	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Belching	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Bilateral Lower Extremity Edema	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Blood in Stool	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Right Leg Hip Pain	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Eye disorders Bloodshot eyes	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Body Aches	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Burning near rectum (likely zoster related)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Bumps on Tongue	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Burning sensation in throat	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders Burning with Urination	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Calf Cramping	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Cellulitis (lesion on knee)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Central Disc Herniation	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Chest Congestion	40.0% 2/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Chest Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Chest Pressure	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Chest tightness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Cardiac disorders CHF Exacerbation	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Chills	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Clear Rhinorrhea	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders Clots in Urine	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Cold	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Collapsed Lung	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Congestion	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Constipation	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	100.0% 3/3 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	44.4% 4/9 • Number of events 7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Cramping (intermittent)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Reproductive system and breast disorders Cramping (menopausal symptoms)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Cramping in Hands & Feet	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Creatinine	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders D-Dimer	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
General disorders Death NOS	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Decrease in Strength	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Decrease in taste	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Reproductive system and breast disorders Decrease Sex Drive	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Dehydration	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Depression	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Dermatitis	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Diarrhea	40.0% 2/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	77.8% 7/9 • Number of events 12 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	60.0% 3/5 • Number of events 6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders Difficulty initiating urinary stream	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Diffuse Erythematous Rash ( extremeties)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Discomfort in Stomach (pain)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Disseminated Zoster	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Dizziness	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 2/6 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Eye disorders Dry Eyes	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Dry Heaving	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Dry Lips	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Dry Mouth	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Dry Skin	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Vascular disorders DVT ( Left subclavala vein)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Dysphagia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Dyspnea (DOE)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	44.4% 4/9 • Number of events 6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders Dysuria	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Ear and labyrinth disorders Ear Ache	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Edema	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	28.6% 2/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Elevated Base Excess (intermittent)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Elevated Creatinine	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Elevated Lactate	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Elevated pH (intermittent)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Elevated PO2 (intermittent)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Elevated WBC	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Epigastric Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Epistaxis (mild & intermittent)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Erythematous (slightly on neck)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Eschai of ight index finger	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Facial Tingling	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Fatigue	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	100.0% 3/3 • Number of events 9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	100.0% 9/9 • Number of events 17 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	100.0% 5/5 • Number of events 17 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	57.1% 4/7 • Number of events 9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 2/6 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Fever	20.0% 1/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	44.4% 4/9 • Number of events 6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	80.0% 4/5 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	28.6% 2/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Finger Parasthesias	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Flushing	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	44.4% 4/9 • Number of events 6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	42.9% 3/7 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Gagging	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Gas	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders General Malaise	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders GERD	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Groin Swelling (post -op site)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Gums/Teeth tender feeling	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Hand Cramping	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Hand- Foot Reaction	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Headaches	40.0% 2/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	55.6% 5/9 • Number of events 11 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Cardiac disorders Heart Palpitations	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hematuria	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hemoptysis	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Hiccups	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Hives	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Hoarse Voice	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Reproductive system and breast disorders Hot flashes	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
General disorders Hyperactive	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Hyperactivity of the Gut	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hyperbilirubinemia	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hypercalcemia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hyperglycemia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hyperkalemia	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hypoalbuminemia	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hypoglycemia	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hypokalemia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	28.6% 2/7 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hypomagnesemia	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hyponatremia	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Hypophosphatemia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Cardiac disorders Hypotension	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Hypothermia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders Incontinence	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Infections and infestations (Bacterium gram neg rods)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders INR	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Insomnia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders itching	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Joint Aches	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Lack of Concentration	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Leakage from rectum	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Left Breast Itchy Rash	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Eye disorders Left Eye Redness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Left Groin Lymph Node Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Left Hip Pain	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Left lower quadrant abdominal pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Left Nipple Bump	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Left Sided Abdominal Pain	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Left Upper Quandrant Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Leg Weakness/numbness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Legs Cramps	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Light Headedness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Hepatobiliary disorders Liver Dysfunction	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Hepatobiliary disorders Liver Failure	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Low Chloride (intermittent)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Low CO2	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Low PCO2 (intermittent)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Low PO2 (intermittent)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Lower Neck Tighness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Cardiac disorders MAPS (in 50's)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Metabolic Acidosis	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Metallic Taste	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Mild Dyspena	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Cardiac disorders Mild Hypovalemia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Mild Increase in Tremor (in off week)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Mild Increasein Intention Tremor	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Mild Neck Soreness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Mild Right Knee Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Mild Sore Throat	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Mouth Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Mouth Sore	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Mucositis	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Muscle Cramps	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Muscle Spasms	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Muscular Pain(Buttocks to toes)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Nasal Congestion	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Nausea	40.0% 2/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	100.0% 3/3 • Number of events 12 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	100.0% 3/3 • Number of events 5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	88.9% 8/9 • Number of events 28 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	100.0% 5/5 • Number of events 21 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	71.4% 5/7 • Number of events 10 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	50.0% 3/6 • Number of events 5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Neck Aches (site of enlarged LN)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Neuropathy	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Neutropenia	20.0% 1/5 • Number of events 8 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Neutropenic Spesis	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Night Sweats	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Nosebleed	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders O2 saturation	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Ocassional Cramping	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Occasional sweating at night	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Occational lightheadedness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders Odor with Urination	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	55.6% 5/9 • Number of events 5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Cardiac disorders Palpitations	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Papular Rash	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Parasthesia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Petechiae Hard Palate	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Pleuritic Chest Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Pneumonia (Probable)	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders Polyuria	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Port Infections and infestations (staphylococcus species, coagulase negative)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Post Nasal Drip	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Presyncopal Episode	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Productive Cough	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Proteinuria	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Pruritic Rash	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	40.0% 2/5 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Eye disorders Ptosis of the right eye	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Pulled Back Muscle	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Rash (mid area of chest)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Rash(below left breast)	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Rash(blotchy dry spots on hands)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Redness & slight bump on right of nose	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Rhinorrhea	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Rib Fracture	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Right Hip Joint Pain	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Right Arm Swelling(bug bite)	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Right Cheek Red Macule	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Eye disorders Right Eye Redness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Right Foot Cramp	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Right Groin Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Right Hand Inflammation(cat scratch)	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Right Hip Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Right Lower Back Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Right Lower Leg Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Right rib Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Right Shoulder Muscle Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Right Side Mouth Sore	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Right Upper Quadrant Pain	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Rigors	60.0% 3/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Runny Nose	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Scrotal and Penile Edema	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Sensory Neuropathy in feet	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Shortness of Breath	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Short-term memory loss	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Sinus Headache	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Cardiac disorders Sinus Tachycardia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Skin Lesion lower back	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Skin tenderness on face	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Slight cough	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Slight dry cough	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Skin and subcutaneous tissue disorders Slight Flushing	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Slight hoarseness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Sore Foot(stepped on nail)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Sore Lymph Nodes(w/ pain)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Sore Throat	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Soreness in mouth	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Soreness of gumlike	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Staphyloccus aureus (MSSA)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Stiff Fingers	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Stomach Cramps	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Stomach Pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Stomach Virus	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders Strong Odor of Urine	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Suprapubic pain	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Sweating	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
General disorders Swollen Cheeks	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Swollen Glands	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
General disorders Swollen Hands & Feets	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Syncope	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders T6/7 & T9/10 Cord Compression	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Cardiac disorders Tachycardia	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	28.6% 2/7 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Taste Changes	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) T-Cell Lymphoproliferative Disorder	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Tenderness in Mouth, Esophagus, Stomach	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Throat Tightening	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Thrombocytopenia	60.0% 3/5 • Number of events 6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Toe Cramping	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Nervous system disorders Toe Parasthesias	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Trace Edema	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Transient Viral Infections and infestations	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Ulcerations in mouth	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Respiratory, thoracic and mediastinal disorders Upper Respitatory Infections and infestations	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 4 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Upper/Mild Back Spams	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Upset Stomach	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Urea Nitrogen	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 2 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders Urgency with urination	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Blood and lymphatic system disorders Uric Acid	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders UTI	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Reproductive system and breast disorders Vaginal dryness (menopausal symptoms)	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Gastrointestinal disorders Vomitiing	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 10 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 2/3 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	66.7% 6/9 • Number of events 24 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	80.0% 4/5 • Number of events 7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	28.6% 2/7 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	16.7% 1/6 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Renal and urinary disorders Weak urine stream	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	20.0% 1/5 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Weakness	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	22.2% 2/9 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Metabolism and nutrition disorders Weight loss	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Musculoskeletal and connective tissue disorders Wide based gait when walking	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	11.1% 1/9 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Yeast Infections and infestations	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 1/3 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/9 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/7 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Infections and infestations Zoster	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	100.0% 3/3 • Number of events 3 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	33.3% 3/9 • Number of events 5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/5 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	14.3% 1/7 • Number of events 1 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).	0.00% 0/6 • Adverse event data was collected up to 30 days post end of treatment for each patient Adverse events were collected by patient reporting and physical exam with an attending and graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).

Additional Information

Owen A. O'Connor, MD, Ph.D.

Columbia University Medical Center

Phone: 212-326-5720

Email: oo2130@cumc.columbia.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place